Preclinical evidence of new opioid modulators for the treatment of addiction

Expert Opinion on Investigational Drugs
Marta Rodríguez-AriasJosé Miñarro

Abstract

Addiction to opiates is one of the most severe forms of substance dependence, and despite a variety of pharmacological approaches to treat it, relapse is observed in a high percentage of subjects. New pharmacological compounds are necessary to improve the outcome of treatments and reduce adverse side effects. Moreover, drugs that act on the opioid system can also be of benefit in the treatment of alcohol or cocaine addiction. AREA COVERED BY THIS REVIEW: Recent preclinical studies of pharmacological agents for the treatment of opiate addiction (2008 to the present date). The reader will be informed of the latest drugs shown in animal models to modify dependence on opiates and the reinforcing effects of these drugs. In addition, reports of the latest studies to test these compounds in models of other drug addictions are reviewed. The classic clinical pharmacotherapy for opiate dependence, involving mu-opioid receptor agonists or antagonists, has not yielded a high success rate in humans. In pharmacotherapy for opioid dependence, new options are emerging and different pharmacological strategies are now being tested.

References

Sep 24, 1999·Pharmacology, Biochemistry, and Behavior·M Rodríguez-AriasL Stinus
Nov 13, 2001·Behavioural Brain Research·C ManzanedoJ Miñarro
Dec 28, 2002·Progress in Neuro-psychopharmacology & Biological Psychiatry·Amparo SerranoJosé Miñarro
Jun 19, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·David W OslinCharles P O'Brien
May 29, 2004·Neuroreport·Carmen ManzanedoJosé Miñarro
Sep 24, 2004·Progress in Neuro-psychopharmacology & Biological Psychiatry·Bruno Ribeiro Do CoutoJose Miñarro
Jan 27, 2005·Neuroreport·Carmen ManzanedoJosé Miñarro
Aug 27, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Stéphanie Caillé, Loren H Parsons
Feb 14, 2006·Proceedings of the National Academy of Sciences of the United States of America·Emmanuel ValjentJean-Antoine Girault
Apr 7, 2006·Journal of Addictive Diseases·Einat PelesMiriam Adelson
Jun 17, 2006·Annual Review of Neuroscience·Steven E HymanEric J Nestler
Apr 20, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Yan ZhouMary Jeanne Kreek
May 3, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Brendan M Walker, George F Koob
Jul 3, 2007·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Xiao-Li WeiJin Li
Sep 8, 2007·The Journal of Pharmacology and Experimental Therapeutics·Allison T KnollWilliam A Carlezon
Oct 12, 2007·The International Journal of Neuropsychopharmacology·Laurent KarilaJean Pierre Lépine
Oct 20, 2007·Pharmacology, Biochemistry, and Behavior·Morteza SaminiShahram Ejtemaei Mehr
Dec 7, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Lily Alvarez-JaimesLoren H Parsons
Feb 12, 2008·Alcoholism, Clinical and Experimental Research·Henry R KranzlerCheryl Oncken
Mar 15, 2008·European Journal of Pharmacology·Alexander KuzminSture Liljequist
Mar 18, 2008·European Journal of Pharmacology·Gad KleinBenjamin Kest
Mar 21, 2008·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Ryan T LaLumiere, Peter W Kalivas
Mar 28, 2008·Progress in Neuro-psychopharmacology & Biological Psychiatry·Elisabeth J Van BockstaeleMichelle E Page
Apr 15, 2008·The International Journal of Neuropsychopharmacology·Stephanie TobinUri Shalev
Apr 17, 2008·British Journal of Pharmacology·D Nutt, A Lingford-Hughes
Jun 26, 2008·Psychopharmacology·Van A Redila, Charles Chavkin

❮ Previous
Next ❯

Citations

Apr 22, 2011·Alcohol and Alcoholism : International Journal of the Medical Council on Alcoholism·Thomas Hillemacher
Aug 13, 2011·Behavioural Pharmacology·Claire Gavériaux-Ruff, Brigitte Lina Kieffer
Jun 10, 2011·Expert Opinion on Investigational Drugs·Thomas HillemacherHelge Frieling
Sep 20, 2011·Trends in Pharmacological Sciences·Amynah A PradhanBrigitte L Kieffer
Jun 28, 2016·Pharmacological Reviews·Louis GendronGraciela Pineyro
Sep 21, 2013·Journal of Psychopharmacology·David J Nutt
Jul 14, 2021·Pharmacology & Therapeutics·Rob Hill, Meritxell Canals

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

CNS & Neurological Disorders Drug Targets
Toni S ShippenbergVladimir I Chefer
Current Drug Abuse Reviews
Milagros Méndez, Marcela Morales-Mulia
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
José A MorónLakshmi A Devi
The Journal of Pharmacology and Experimental Therapeutics
Richard M van RijnJennifer L Whistler
© 2021 Meta ULC. All rights reserved